PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 260 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,611,036 | +22.4% | 117,700 | +59.9% | 0.01% | +12.5% |
| Q2 2023 | $2,949,152 | +460.2% | 73,600 | +470.5% | 0.01% | +700.0% |
| Q1 2023 | $526,449 | -58.9% | 12,900 | -23.1% | 0.00% | -66.7% |
| Q1 2022 | $1,280,000 | -72.7% | 16,776 | -78.5% | 0.00% | -75.0% |
| Q4 2021 | $4,692,000 | -59.3% | 77,976 | -62.1% | 0.01% | -60.0% |
| Q3 2021 | $11,518,000 | -46.9% | 205,676 | -42.4% | 0.03% | -47.4% |
| Q2 2021 | $21,680,000 | +477.4% | 357,276 | +566.9% | 0.06% | +470.0% |
| Q1 2021 | $3,755,000 | +134.4% | 53,576 | +100.1% | 0.01% | +150.0% |
| Q4 2020 | $1,602,000 | +8.0% | 26,776 | +8.5% | 0.00% | 0.0% |
| Q3 2020 | $1,484,000 | +435.7% | 24,676 | +198.2% | 0.00% | +300.0% |
| Q1 2020 | $277,000 | -89.1% | 8,276 | -85.2% | 0.00% | -83.3% |
| Q4 2019 | $2,540,000 | +6.8% | 56,076 | -10.2% | 0.01% | 0.0% |
| Q3 2019 | $2,378,000 | -80.9% | 62,476 | -78.2% | 0.01% | -80.6% |
| Q2 2019 | $12,437,000 | +36.3% | 285,976 | +19.3% | 0.03% | +34.8% |
| Q1 2019 | $9,126,000 | -21.5% | 239,776 | -11.3% | 0.02% | -28.1% |
| Q4 2018 | $11,632,000 | +54.8% | 270,376 | +76.9% | 0.03% | +77.8% |
| Q3 2018 | $7,514,000 | -25.5% | 152,876 | -30.8% | 0.02% | -33.3% |
| Q4 2017 | $10,092,000 | +1138.3% | 221,076 | +918.8% | 0.03% | +1250.0% |
| Q3 2017 | $815,000 | -67.3% | 21,700 | -58.4% | 0.00% | -75.0% |
| Q2 2017 | $2,489,000 | +279.4% | 52,176 | +262.9% | 0.01% | +300.0% |
| Q1 2017 | $656,000 | +4.6% | 14,376 | -25.9% | 0.00% | 0.0% |
| Q4 2016 | $627,000 | +31.7% | 19,400 | +39.6% | 0.00% | 0.0% |
| Q3 2016 | $476,000 | +131.1% | 13,900 | +127.9% | 0.00% | +100.0% |
| Q2 2016 | $206,000 | -37.6% | 6,100 | +41.9% | 0.00% | -50.0% |
| Q4 2015 | $330,000 | -95.1% | 4,300 | -93.8% | 0.00% | -96.2% |
| Q3 2014 | $6,705,000 | +235.2% | 69,176 | +217.7% | 0.05% | +231.2% |
| Q2 2014 | $2,000,000 | +525.0% | 21,776 | +375.9% | 0.02% | +433.3% |
| Q1 2014 | $320,000 | – | 4,576 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |